# What Controls Should Clinics Put on Clinical AI Agents in 2026?

getpulse.care · September 27, 2026

> Direct Answer: Clinical AI Agents Need Scoped, Supervised Authority Clinical AI agents should not receive unrestricted control of patient records...

## Direct Answer: Clinical AI Agents Need Scoped, Supervised Authority

Clinical AI agents should not receive unrestricted control of patient records, clinical systems, prescribing, scheduling, messaging, or external communications. The appropriate control model gives each agent a narrowly defined role, a documented set of permitted actions, access only to the minimum necessary data, and a clear threshold at which a clinician, administrator, or another human must approve the next step. This is especially important for agents that can operate a software interface, retrieve information, summarize records, draft notes, or take multi-step actions rather than merely answer a question.

**Also worth reading:** [Which Clinical AI Pilot Metrics Actually Prove Value for Clinics and Care Networks?](https://getpulse.care/knowledge/which_clinical_ai_pilot_metrics_actually_prove_value_for_clinics_and_care_networks.php) · [What is a clinical AI risk management framework and how do clinics implement it for patient pulse monitoring?](https://getpulse.care/knowledge/what_is_a_clinical_ai_risk_management_framework_and_how_do_clinics_implement_it_for_patient_pulse_monitoring.php) · [How Will Generative AI Care Coordination Agents Work in Clinics by 2027?](https://getpulse.care/knowledge/how_will_generative_ai_care_coordination_agents_work_in_clinics_by_2027.php)

The reason is not that every clinical agent is unsafe. Useful automation already exists in areas such as draft documentation, patient outreach, prior-authorization preparation, and administrative coordination. The problem is that an agent combines several capabilities that can fail differently: a model can misunderstand an instruction, retrieve outdated information, mishandle an identifier, or follow a malicious instruction embedded in a document. A tool-enabled agent can then turn an imperfect response into a real-world action. Reported concerns about unapproved healthcare AI and security incidents therefore argue for stronger controls, not an assumption that all clinical automation is ineffective.

As of the stated date of 27 September 2026, a defensible clinic policy should distinguish four authority levels: read-only assistance, draft creation, reversible operational action, and irreversible clinical action. Routine summaries and draft notes may fall into the first two levels. Updating a non-clinical work queue may be acceptable at the third level if it is logged and reversible. Prescribing, ordering diagnostic tests, changing a medication dose, releasing a high-risk communication, or modifying a legal clinical record should remain human-authorized unless a validated, regulated system explicitly supports that level of operation.

## How Clinical AI Agent Controls Work in Practice

The central control is a permission contract attached to the agent rather than to a vague job description. It should identify the system, the patient or population, the permitted data fields, the tools the agent may call, the actions it may take, the maximum number of steps, the time window, and the conditions requiring escalation. For example, an intake agent might be allowed to read unreviewed patient-submitted forms, ask clarifying questions, and write a draft to a separate intake queue. It should not automatically update allergies, infer a diagnosis, send medication instructions, or search an entire chart without an authenticated user context.

A second control is pre-action approval. Some actions can execute automatically because their impact is low and the action can be undone; others need a clinician to approve a preview before execution. The preview should show the source record, the proposed change, relevant patient identity, the model’s confidence or uncertainty indicators, and the reason for the proposed action. A useful operational rule is to require confirmation for any action involving prescriptions, test orders, emergency escalation, consent, billing-sensitive changes, external disclosures, or access to records across organizational boundaries.

A third control is observability. Every prompt, retrieval, tool call, proposed change, approval, execution, failure, and rollback should be recorded in an audit trail. Logs need timestamps, the identity of the initiating user, the agent and model version, the patient identifier in a protected form, the tool used, and the outcome. The system should also retain enough context to reconstruct why an action occurred. A transcript that only records the final answer is inadequate when an agent operated several connected applications. Healthcare organizations should sample logs regularly and investigate unexpected tool use, repeated failures, bulk access, permission changes, and actions outside the agent’s assigned scope.

Finally, controls need to be enforced technically. Policies should be enforced through identity and access management, least-privilege credentials, scoped application programming interfaces, allowlisted tools, data-loss controls, secrets management, and role-based approval. A written rule saying that an agent “must not prescribe” is not enough if the same agent still holds a credential that can prescribe. Technical enforcement should be backed by a named owner who can disable the agent, rotate credentials, and pause integrations when a model, vendor, or data source changes.

## Why Traditional Clinical Governance Is Not Enough

Traditional clinical governance reviews protocols, evidence, quality metrics, and professional accountability. It was not designed for software that can independently choose tool sequences at runtime. A clinician may be accountable for the final decision, but an agent can still create workload, duplicate actions, expose sensitive data, or influence decisions before that review occurs. The control problem is therefore both technical and operational: the system must limit what the agent can do, while the organization must make sure humans can understand and challenge what it did.

The distinction between ordinary clinical decision support and an agent is important. A decision-support tool usually presents a recommendation to a clinician, who remains in the decision loop. An agent can plan, call tools, interpret results, and proceed toward a goal. That extra autonomy changes the risk profile even when the underlying model produces the same kind of medical recommendation. The more systems the agent can access, the more opportunities exist for errors to propagate. An identity mistake in one system can become a duplicate update in another, a message to a patient, or a scheduling error visible to the care team.

Healthcare organizations also face a rapidly expanding shadow-AI problem. The supplied research context cites an Imprivata-related report claiming that 72% of healthcare organizations run unapproved AI as autonomous agents enter clinical care. The precise methodology and population should be checked against the original report before using that figure as a universal benchmark, but the number illustrates a governance gap. Staff may use consumer AI tools for note drafting, coding, patient communication, or data summarization without those uses being included in formal risk reviews. A policy limited to purchased enterprise products will miss this behavior.

The appropriate response is proportional governance. Drafting behind a clinician review may deserve a moderate level of review, while an agent that can place orders or transmit prescriptions requires stronger technical controls, validation, monitoring, and incident response. Risk should be assessed by action impact, reversibility, data sensitivity, autonomy, and clinical context—not by the vendor label “AI assistant.”

## Comparison: Four Approaches to Controlling Clinical Agents

| Feature | Read-only agent | Draft-generating agent | Supervised action agent | Highly autonomous clinical agent |
| --- | --- | --- | --- | --- |
| Typical use | Search, retrieve, summarize | Draft notes, messages, coding suggestions | Update queues, schedule approved work, prepare orders | Place orders, prescribe, or communicate with limited review |
| Data access | Minimum necessary, de-identified where possible | Relevant patient record sections | Scoped access to required applications | Broad access may be technically required |
| Human approval | Usually not for reading | Clinician reviews before release | Approval based on action risk | Mandatory for irreversible actions in most clinics |
| Key controls | Access logging, retrieval limits | Prompt review, source display, no auto-send | Pre-action preview, allowlisted tools, rollback | Stronger validation, monitoring, and explicit exceptions |
| Main risk | Excessive disclosure or retrieval errors | Inaccurate or unsupported draft | Incorrect tool execution or identity mismatch | Rapid propagation of serious errors |
| Suitable initial stage | Yes | Yes, with review | Yes, for selected workflows | Generally not a first deployment |

The table shows a staged approach rather than a ranking. Read-only agents can still expose sensitive data, so “read-only” is not equivalent to risk-free. Draft-generating agents need review because plausible language can conceal factual errors. Supervised action agents offer useful efficiency, but their permissions must be limited to approved workflows. Highly autonomous systems may be appropriate in tightly bounded, validated settings, but clinics should not begin there unless they have the governance, clinical safety, cybersecurity, and legal resources to support the arrangement.
An alternative is to keep all clinical AI in a non-executing role and use deterministic workflow software for approved actions. This is slower and may require more staff time, but it reduces the number of dynamic decisions delegated to a model. Another alternative is to purchase an integrated clinical platform with embedded audit and approval controls. That can be easier to govern than a separate agent connected through broad credentials, although it does not remove the need to configure permissions and review outputs. A third option is a local or on-premise deployment, which may improve data-control options but can increase infrastructure and maintenance costs. On-premise medical AI research cited in the supplied context reflects interest in reliable clinical deployment, but physical location alone does not establish safety.

## Practical Controls Clinics Can Implement

Start with an inventory of every AI tool, including purchased products, browser extensions, messaging assistants, coding tools, and personal accounts used for work. Record the data each tool receives, the users involved, the actions it can take, and whether anyone has approved its use. Block unmanaged tools from systems containing protected health information, and provide an approved alternative where feasible. This inventory should have an owner and a review date, because a tool can change its permissions or terms after deployment.

Next, classify workflows by impact. A low-impact workflow might be formatting a non-clinical list or summarizing administrative instructions. A medium-impact workflow might draft a clinical note or prior-authorization packet. A high-impact workflow includes prescribing, ordering, changing a care plan, communicating treatment instructions, or deciding that a patient can safely skip follow-up. Set approval rules from that classification. Require a human to inspect the underlying source and the proposed output for clinical content, and require a second review where a mistake could cause serious harm or affect a vulnerable patient.

Technical implementation should use separate service identities, short-lived credentials, least-privilege scopes, and tool allowlists. The agent should not inherit a clinician’s full access merely because a clinician initiated a conversation. Where possible, use read-only access first, sandbox the output, and require an explicit commit step. Configure rate limits, patient-context checks, duplicate-action detection, and automatic stopping after a defined number of failed attempts. Test with synthetic records and adversarial examples before connecting to live systems.

Finally, establish a pause-and-report process. Staff should know how to stop an agent, preserve the relevant record, and report a suspected incident without fear of blame for a good-faith report. The security team should rotate credentials and revoke sessions if necessary. The clinical lead should assess patient impact, and the privacy and legal teams should determine notification obligations. The objective is not merely to prevent every error; it is to make errors detectable, reversible where possible, and correctable quickly.

## Common Mistakes and When to Act

One common mistake is treating a benchmark score as proof of clinical fitness. Models can perform well on curated test sets while failing on incomplete records, local terminology, unusual patient circumstances, or stale guidance. Another is assuming that human review solves the problem. If clinicians must review dozens of routine messages, “human in the loop” can become rubber-stamping, especially when the system produces fluent output at high volume. Reviewer training, sampling, escalation thresholds, and workload limits are part of the control system.

A second mistake is giving an agent broad credentials and trying to compensate with a policy document. If the agent can access a charting system, patient portal, scheduling system, and external messaging tool, a compromised prompt or unexpected tool sequence may affect all four. Another mistake is measuring success only by time saved. Include near misses, inappropriate access, duplicate actions, unsupported recommendations, override rates, rollback frequency, and incidents per 1,000 agent actions. For a new system, a reasonable starting threshold is zero unreviewed irreversible clinical actions, with every such attempt generating an alert and review.

A third mistake is treating cybersecurity, clinical safety, and privacy as separate approval processes. A system can be secure in narrow technical terms while still producing an unsafe clinical suggestion, or clinically validated while exposing more data than necessary. Review the whole chain, including model providers, downstream tools, data retention, subcontractors, and user configuration.

Act immediately when an agent is used with protected health information without an approved agreement, when staff cannot identify who is accountable, or when the agent can send or commit clinical changes without review. Pause deployment after a material model or tool update, a new integration, a data-source change, or evidence of anomalous behavior. Review the controls at least quarterly during early operation, and at least annually for stable, low-risk workflows. High-impact agents should receive more frequent review, especially when clinical policies, regulations, or model versions change.

## Cost, Pricing, and Buying Decisions

There is no reliable universal price for clinical AI agent controls because costs depend on whether the clinic buys a regulated product, assembles a custom system, or enforces controls internally. Budget categories include software licenses or usage fees, model inference, identity and access management, audit storage, integration work, security testing, clinical validation, staff training, monitoring, and legal review. A low monthly subscription may be inexpensive for drafting, but it can become costly if it requires broad chart access, manual review, custom interfaces, or incident response.

The research context names several types of offerings: curated drug information from InpharmD, agent-skill verification from Vett, connectivity tools such as Alloy Automation MCP, and clinical or administrative agents from vendors including Oracle Health. These examples show different control surfaces rather than a single category of product. Curated reference data can improve factual grounding, but it does not guarantee that an agent will select the correct source or apply it to a patient. Connectivity tools can expand capability, but each connection expands the blast radius of a failure. Skill verification can reduce supply-chain risk, but it is not a substitute for permissions, clinical review, or local testing.

When comparing vendors, ask for evidence about audit logs, model and data retention, role-based access, regional hosting, subcontractor use, incident notification, validation evidence, export rights, and what happens when the vendor changes a model. A contract should state who owns the data, whether the vendor trains on it, how long logs are kept, and how customers can terminate integrations. For getpulse.care and similar care-coordination platforms, the relevant buying question is whether the system can coordinate patient-pulse workflows while keeping clinical and external actions scoped, reviewable, and configurable for each clinic or care network.

The best option is not automatically the most autonomous or most feature-rich one. Select a product according to the workflow’s risk, the organization’s ability to supervise it, and the consequences of failure. Validate with representative records, test edge cases, and require a staged rollout. A modest fee for a product with strong controls may be more economical than a cheaper agent whose errors create review, cleanup, and reputational costs.

## The Defensive Standard for 2026

Clinical AI agents are best understood as controlled actors inside a clinical system, not as ordinary chat interfaces and not as independent digital clinicians. They may retrieve information, prepare drafts, or execute approved steps, but their authority should be proportional to the harm that could result. The strongest practical pattern is a narrow role, minimum necessary data, allowlisted tools, previews for consequential actions, complete auditability, and an immediate human stop mechanism.

For clinics and care networks, the immediate priority is to inventory and govern what already exists. Identify unapproved use, separate drafting from execution, and set firm rules for prescribing, ordering, patient messaging, and record changes. Then introduce supervised agents in workflows where the benefit is measurable and the error can be caught or reversed. The supplied context of 72% unapproved organizational AI, emerging agent-security incidents, and expanded clinical-agent products makes this a current operating concern, but the precise figures and events should be verified against original sources before they are used in a formal business case.

The right standard is neither total prohibition nor unrestricted autonomy. It is accountable automation with explicit boundaries. If a clinic cannot answer who can authorize an action, which data the agent sees, how the action is logged, or how the system is stopped, it is not ready to grant that agent broader control. This approach preserves the potential efficiency of clinical AI while keeping patient safety, privacy, and professional responsibility at the center of care delivery.

## Quick answers

### Can clinical AI agents prescribe or place orders autonomously?

Most clinics should not permit that level of autonomy as a starting policy. A prescribing or ordering workflow generally needs a licensed clinician to review the patient, source information, and proposed action before execution, unless a specifically validated and regulated arrangement defines the authority and monitoring controls.

### What is the safest first use of a clinical AI agent?

A read-only or draft-generating role is usually the safest starting point, such as summarizing administrative information or drafting a note for clinician review. Even these uses require minimum-necessary access, source visibility, audit logging, and a policy against automatically sending or committing the output.

### How do we prevent an AI agent from accessing too much patient data?

Use separate service identities, least-privilege permissions, scoped APIs, patient-context checks, de-identification where possible, and tool allowlists. Access should be limited to the fields and systems required for the specific workflow, with unusual volume or cross-patient access triggering an alert.

### Is on-premise clinical AI safer than a cloud service?

On-premise deployment can provide more direct control over infrastructure and data location, but it does not automatically solve model errors, prompt injection, credential abuse, or unsafe actions. The right comparison includes vendor governance, validation, monitoring, integration design, maintenance burden, and the quality of the clinical workflow.

### What should a clinic do after an AI agent makes a mistake?

Pause the affected integration, preserve logs and the relevant record, revoke or rotate exposed credentials, assess patient impact, and correct or roll back the action where possible. The clinical, privacy, security, and legal owners should determine whether notifications or regulatory reporting are required, then review the controls before restarting.

Canonical: https://getpulse.care/knowledge/what_controls_should_clinics_put_on_clinical_ai_agents_in_2026.php
Markdown: https://getpulse.care/knowledge/what_controls_should_clinics_put_on_clinical_ai_agents_in_2026.php/index.md